Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can the standard chemotherapeutic regimen be improved upon for small-cell lung cancer?

Nature Clinical Practice Oncology volume 3, pages 360–361 (2006)Cite this article

boxed-textThatcher N et al. (2005) Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 23: 8371–8379

The optimal therapeutic regimen for patients with small-cell lung cancer and good performance status remains platinum-based chemotherapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pujol JL et al. (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83: 8–15

    Article  CAS  Google Scholar 

  2. Sundstrom S et al. (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20: 4665–4672

    Article  CAS  Google Scholar 

  3. Pujol JL et al. (2001) Etoposide plus cisplatin with or without the combination of 4´-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93: 300–308

    Article  CAS  Google Scholar 

  4. Tjan-Heijnen VC et al. (2002) An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 13: 1519–1530

    Article  CAS  Google Scholar 

  5. Slee EA et al. (2004) To die or not to die: how does p53 decide? Oncogene 23: 2809–2818

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Professor in the Department of Medical Oncology at Yale Cancer Center, New Haven, CT, USA

    Amanda Psyrri

  2. Professor of Medicine and Head of the Department of Medical Oncology at the Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    George Fountzilas

Authors
  1. Amanda Psyrri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Fountzilas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Fountzilas.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Psyrri, A., Fountzilas, G. Can the standard chemotherapeutic regimen be improved upon for small-cell lung cancer?. Nat Rev Clin Oncol 3, 360–361 (2006). https://doi.org/10.1038/ncponc0519

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0519

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing